Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ARCHIVE
ARCHIVE
- R-Tech Ueno Discontinues PI Study of Hypotrichosis Drug in UK
August 8, 2011
- Marketing Expenses Up 1.5% to US$91 Bil. in 2010: CSD Survey
August 8, 2011
- Taiho's TAS-102 Prolongs OS in mCRC: JSMO Annual Meeting
August 8, 2011
- Oncology Products to Contribute to Astellas' Business from 2018 Onward: President Hatanaka
August 8, 2011
- Avastin's Efficacy in Combination with FOLFIRI for Colon Cancer Confirmed in Domestic PII Study
August 8, 2011
- Shionogi to Enter Chinese Market by Acquiring Local Company
August 8, 2011
- BioWa Licenses Potelligent Technology to arGEN-X
August 8, 2011
- Medipal, JCR Pharm. Announce Tie-up; Medipal to Invest in Drug Development
August 8, 2011
- Toyama Chemical to Construct New Pharmacology Research Lab
August 8, 2011
- RaQualia Licenses 5-HT4 Partial Agonist to CJ CheilJedang in South Korea
August 8, 2011
- Fujifilm, DRL Announce Plans to Establish Generic Drugs JV in Japan
August 8, 2011
- Astellas Transfers Investigational Anti-arrhythmic Agent to Merck Subsidiary
August 8, 2011
- Revision Proposed to 70% Rule for Pricing of New Generics
August 8, 2011
- Teijin Pharma's Gout Agent Febuxostat Launched in South Korea
August 8, 2011
- Korosho Orders 10-Day Suspension of Operations for Kobayashi Medical
August 8, 2011
- M3 to Promote Clinical Study Support Business by Acquiring SMO
August 8, 2011
- LTT Bio-Pharma to License Inhalant PC-SOD to CKD in South Korea
August 1, 2011
- Transfer of Part of PMDA Functions to Osaka Proposed in Kansai Sogo Tokku Plan
August 1, 2011
- Astellas Licenses Transplant Viremia Prevention Vaccine from Vical
August 1, 2011
- Chugai Applies for Approval of Pulmozyme for Cystic Fibrosis
August 1, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…